Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Fate rapeutics

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022

Upgrades

Benzinga · Jul 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022

Upgrades

Benzinga · Jul 11, 2022

Recap: Fate Therapeutics Q1 Earnings

Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · May 4, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Looking Into Fate Therapeutics's Return On Capital Employed

Benzinga Pro data, Fate Therapeutics (NASDAQ:FATE) reported Q4 sales of $17.07 million. Earnings fell to a loss of $68.62 million, resulting in a 58.45% decrease from last quarter.

Benzinga · Mar 2, 2022

Fate Therapeutics's Earnings: A Preview

Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Fate Therapeutics will report an earnings per share (EPS) of $-0.67.

Benzinga · Feb 25, 2022

Earnings Outlook For Fate Therapeutics

Benzinga · Feb 25, 2022

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.